Entera Bio Ltd. financial data

Symbol
ENTX on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
Kiryat Hadassah, Minrav Building, Fifth Floor, Jerusalem, Israel
State of incorporation
Israel
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 822 % +31.5%
Debt-to-equity 16.2 % -20.9%
Return On Equity -107 % +1.97%
Return On Assets -92.3 % -1.64%
Operating Margin -71.4K % -1350%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 36.8M shares +27.8%
Common Stock, Shares, Outstanding 36.5M shares +26.7%
Entity Public Float 20.7M USD -37.1%
Common Stock, Value, Issued 1K USD
Weighted Average Number of Shares Outstanding, Basic 37.6M shares +30.6%
Weighted Average Number of Shares Outstanding, Diluted 37.6M shares +30.6%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 42K USD
Cost of Revenue 42K USD
Research and Development Expense 4.3M USD -11.6%
General and Administrative Expense 4.93M USD -5.14%
Operating Income (Loss) -9.21M USD +7.85%
Nonoperating Income (Expense) 33K USD -34%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -3.02M USD -28.6%
Income Tax Expense (Benefit) 0 USD -100%
Net Income (Loss) Attributable to Parent -9.18M USD +7.56%
Earnings Per Share, Basic 0.26 USD/shares -23.5%
Earnings Per Share, Diluted 0.26 USD/shares -23.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 6.92M USD -8.83%
Accounts Receivable, after Allowance for Credit Loss, Current 42K USD
Other Assets, Current 89K USD -66.2%
Assets, Current 7.34M USD -8.43%
Deferred Income Tax Assets, Net 14K USD -6.67%
Property, Plant and Equipment, Net 65K USD -39.8%
Operating Lease, Right-of-Use Asset 316K USD -24.8%
Assets 7.74M USD -9.62%
Accounts Payable, Current 184K USD -67.4%
Contract with Customer, Liability, Current 0 USD -100%
Liabilities, Current 1.11M USD -45.2%
Operating Lease, Liability, Noncurrent 147K USD -45.8%
Liabilities 1.29M USD -44.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax 41K USD 0%
Retained Earnings (Accumulated Deficit) -112M USD -8.96%
Stockholders' Equity Attributable to Parent 6.45M USD +3.46%
Liabilities and Equity 7.74M USD -9.62%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.86M USD -15.7%
Net Cash Provided by (Used in) Financing Activities 30K USD
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 140M shares 0%
Common Stock, Shares, Issued 36.5M shares +26.7%
Common Stock, Par or Stated Value Per Share 0 ILS/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.83M USD -13.1%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6.99M USD -8.9%
Deferred Tax Assets, Valuation Allowance 19.5M USD +10.3%
Deferred Tax Assets, Gross 19.5M USD +10.2%
Operating Lease, Liability 390K USD +329%
Depreciation 13K USD -7.14%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid 454K USD
Operating Lease, Liability, Current 162K USD +23.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 184K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 184K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.14 pure -12.5%
Deferred Income Tax Expense (Benefit) 0 USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 64K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 86K USD
Deferred Tax Assets, Operating Loss Carryforwards 17.4M USD +13%
Lessee, Operating Lease, Liability, to be Paid, Year Four 83K USD
Deferred Tax Assets, Net of Valuation Allowance 14K USD -67.4%